Pfizer & Biohaven Combine Forces; Vying for Valuable Upside
Continuing the acquisition spree after absorbing Arena
Pharmaceuticals and Reviral Ltd. to meet unmet patients’ needs,
Pfizer Inc. (NYSE: PFE), the global pharmaceutical and
biotechnology company, has agreed to snap up migraine
drugmaker Biohaven Pharmaceutical Holding Company Ltd.
(BHVN). The cash deal is valued at $11.6 billion, to be
funded by Pfizer with current cash in hand. Following the
news, shares of Pfizer rose 1.66% on Tuesday at the close, while
shares of Biohaven skyrocketed 68.4%. The deal followed the
strategic partnership deal between the two, entered in November
2021, for the commercialization of rimegepant and
zavegepant outside the U.S.
から 6 2022 まで 7 2022
から 7 2021 まで 7 2022